NNC0487-0111 for Weight Loss Maintenance
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
Recruiting
Phase 3
Interventional Study
Obesity
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 600 (estimated)
- Sponsor
- Novo Nordisk A/S · Industry
Who this trial is looking for
This trial is looking for adults who have excess body weight to see if the medicine NNC0487-0111 can help them keep off weight they have lost. Participants will receive either the medicine or a placebo injection once a week.
Are You a Good Fit for This Trial?
You may be able to join if
- I am 18 years or older.
- I am male or female.
You may not be able to join if
- My HbA1c level is 6.5% or higher.
- I have a history of type 1 or type 2 diabetes.
- I have taken certain diabetes medications before the study.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decid…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Male or female (sex at birth).
* Age 18 years or above at the time of signing the informed consent.
Exclusion Criteria:
* Glycated haemoglobin (HbA1c) greater than or equal to ≥ 6.5% \[48 millimoles per mole (mmol/mol)\] as measured by the central laboratory at screening.
* …
Contacts